Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Liver International · 2026
DOI: 10.1111/liv.70534 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Liver International, 2026. Verfasst von Teng-Yu Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, Taichung Veterans General Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Ministry of Health and Welfare, National Science and Technology Council, Taichung Veterans General Hospital.
Abstract (Originalsprache)
Background & Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is highly prevalent; however, MASLD‐related hepatocellular carcinoma (HCC) has a relatively low incidence, posing a public health challenge in identifying high‐risk patients. We aimed to develop a widely implementable scoring system for HCC surveillance.
Methods
Using Taiwan's National Health Insurance Database, we identified 232 125 patients with newly diagnosed MASLD between 2009 and 2020 as the development cohort. External validation was performed in an independent cohort of 28 045 MASLD patients from Hong Kong. Both cumulative incidences of and hazard ratios (HRs) for HCC development were analysed after adjusting for competing mortality.
Results
In the development cohort, the 10‐year cumulative incidence of HCC was 0.41% (95% CI, 0.36%–0.46%). A multivariable Fine–Gray subdistribution hazards model identified cirrhosis, age, male sex, and diabetes mellitus (CAMD) as key risk determinants. These variables were weighted to develop the CAMD score (range: 0–21 points). The concordance (c) indices for HCC prediction in the development cohort were 0.79 (95% CI, 0.76–0.82), 0.80 (95% CI, 0.77–0.82), and 0.80 (95% CI, 0.78–0.82) at 3, 5, and 10 years, respectively. In the validation cohort in Hong Kong, the corresponding c indices were 0.76 (95% CI, 0.69–0.82), 0.76 (95% CI, 0.71–0.81), and 0.73 (95% CI, 0.69–0.77). The predicted and observed HCC probabilities were well‐calibrated in both cohorts. A CAMD score > 13 identified high‐risk patients, with an average annual HCC incidence exceeding 0.2%.
Conclusion
The CAMD score is an easily calculable tool that can facilitate large‐scale HCC surveillance in MASLD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology & Hepatology, Taichung Veterans General Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Medical Data Analytics Centre, The Chinese University of Hong Kong, Hong Kong.
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
- State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
- Institute of Biomedical Informatics, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
ORCID-Profile: Teng-Yu Lee, Yao-Chun Hsu, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
Förderung
- Ministry of Health and Welfare
- National Science and Technology Council
- Taichung Veterans General Hospital
- Taipei Veterans General Hospital
Zitieren
APA
Lee, T. Y., Song, S. J., Ho, H. J., Wong, G. L., Hsu, Y. C., Wong, V. W., Yip, T. C., & Wu, C. Y. (2026). Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. https://doi.org/10.1111/liv.70534
Vancouver
Lee TY, Song SJ, Ho HJ, Wong GL, Hsu YC, Wong VW, et al. Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2026. doi:10.1111/liv.70534
BibTeX
@article{Lee2026,
author = {Lee, Teng-Yu and Song, Sherlot Juan and Ho, Hsiu J and Wong, Grace Lai-Hung and Hsu, Yao-Chun and Wong, Vincent Wai-Sun and Yip, Terry Cheuk-Fung and Wu, Chun-Ying},
title = {Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70534}
}
EUVIMED